Vir Biotechnology Inc (VIR) NPV

Sell:$6.04Buy:$6.05$0.14 (2.36%)

NASDAQ:0.39%
Prices delayed by at least 15 minutes
Sell:$6.04
Buy:$6.05
Change:$0.14 (2.36%)
Deal now
Prices delayed by at least 15 minutes
Sell:$6.04
Buy:$6.05
Change:$0.14 (2.36%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Key people

Marianne De Backer
Chief Executive Officer, Director
Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Maninder Hora
Executive Vice President, Chief Technical Operations Officer
Vanina De Verneuil
Executive Vice President, General Counsel, Corporate Secretary
Mark Eisner
Executive Vice President, Chief Medical Officer
Vicki L. Sato
Independent Chairman of the Board
Norbert W. Bischofberger
Independent Director
Ramy Farid
Independent Director
Jeffrey S. Hatfield
Independent Director
Robert J. More
Independent Director
Click to see more

Key facts

  • EPIC
    VIR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92764N1028
  • Market cap
    $732.66m
  • Employees
    408
  • Shares in issue
    138.24m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.